Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
Portfolio Pulse from Vandana Singh
Ionis Pharmaceuticals Inc has released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS). The trial met its primary efficacy endpoint with a significant reduction in triglyceride levels. The drug also showed a 100% reduction in acute pancreatitis events compared to placebo. Ionis plans to file a New Drug Application in early 2024 with the FDA. Following the news, IONS shares are up 7.83%.
September 26, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals' olezarsen shows promising results in Phase 3 trial, leading to a rise in IONS shares.
The positive results from the Phase 3 trial of olezarsen, a drug developed by Ionis Pharmaceuticals, have led to a significant increase in the company's stock price. The drug's success in reducing triglyceride levels and acute pancreatitis events, along with the company's plans to file a New Drug Application with the FDA in 2024, are likely to have contributed to this increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100